Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07762313
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Humacyte, Inc.Not Yet RecruitingPhase 3
NCT07762313Not Yet Recruiting
Phase 3
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular...Humacyte, Inc.
NCT07762391
Pelvic Floor Muscle Exercise and Progressive Muscle Relaxation for Stress Urinary IncontinenceKaramanoğlu Mehmetbey UniversityCompletedNot Applicable
NCT07762391Completed
Not Applicable
Pelvic Floor Muscle Exercise and Progressive Muscle Relaxation for Stress Urinar...Karamanoğlu Mehmetbey Uni...
NCT07762469
Diagnostic Performance of a Flexible Penile Monitoring System for EDBin XuNot Yet Recruiting
NCT07762469Not Yet Recruiting
—
Diagnostic Performance of a Flexible Penile Monitoring System for EDBin Xu
NCT07762404
Reconstruction of First Web Space After Trauma and BurnSohag UniversityNot Yet RecruitingNot Applicable
NCT07762404Not Yet Recruiting
Not Applicable
Reconstruction of First Web Space After Trauma and BurnSohag University
NCT07764263
Contextualizing Care for Patients With a Serious IllnessRadboud University Medical CenterCompletedNot Applicable
NCT07764263Completed
Not Applicable
Contextualizing Care for Patients With a Serious IllnessRadboud University Medica...
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
NCT07763171
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaGruppo Oncologico del Nord-OvestNot Yet RecruitingPhase 3
NCT07763171Not Yet Recruiting
Phase 3
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-neg...Gruppo Oncologico del Nor...
NCT07764341
Supervised Exercise During Neoadjuvant Chemotherapy for Breast CancerBahrain Oncology CenterNot Yet RecruitingNot Applicable
NCT07764341Not Yet Recruiting
Not Applicable
Supervised Exercise During Neoadjuvant Chemotherapy for Breast CancerBahrain Oncology Center
NCT07763795
Effects of BFRT on Glycemic Control, Nerve Conduction, Functional Outcomes and QOL in Individuals With Type 2 DiabetesSuperior UniversityActive Not RecruitingNot Applicable
NCT07763795Active Not Recruiting
Not Applicable
Effects of BFRT on Glycemic Control, Nerve Conduction, Functional Outcomes and Q...Superior University
NCT07763912
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.ADIUMCompletedNot Applicable
NCT07763912Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07761936
Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor FluctuationsUniversita di VeronaRecruitingPhase 3
NCT07761936Recruiting
Phase 3
Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fl...Universita di Verona
NCT07764133
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian CancerUniversity of Tennessee Graduate School of MedicineRecruiting
NCT07764133Recruiting
—
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation a...University of Tennessee G...
NCT07763951
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763951Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07762963
Turkish Validation of the Core Life Activities ScaleTokat Gaziosmanpasa UniversityNot Yet Recruiting
NCT07762963Not Yet Recruiting
—
Turkish Validation of the Core Life Activities ScaleTokat Gaziosmanpasa Unive...
NCT07762053
Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomonitor TonometerEyeCBetter CorporationNot Yet RecruitingNot Applicable
NCT07762053Not Yet Recruiting
Not Applicable
Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomon...EyeCBetter Corporation
NCT07762859
Wearable Ambulatory Vs. Office BP in HemodialysisGangnam Severance HospitalNot Yet RecruitingNot Applicable
NCT07762859Not Yet Recruiting
Not Applicable
Wearable Ambulatory Vs. Office BP in HemodialysisGangnam Severance Hospita...
NCT07764003
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHsHangzhou Highlightll Pharmaceutical Co., LtdNot Yet RecruitingPhase 2
NCT07764003Not Yet Recruiting
Phase 2
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Re...Hangzhou Highlightll Phar...
NCT07763587
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management RegimenFirst Teaching Hospital of Tianjin University of Traditional Chinese MedicineNot Yet RecruitingNot Applicable
NCT07763587Not Yet Recruiting
Not Applicable
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Ben...First Teaching Hospital o...
NCT07762352
Ankle Brace vs Functional Taping In Adolescents With Chronic Ankle InstabilityEscola Superior de Saude do AlcoitaoCompletedNot Applicable
NCT07762352Completed
Not Applicable
Ankle Brace vs Functional Taping In Adolescents With Chronic Ankle InstabilityEscola Superior de Saude...
Result Breakdown
Not yet recruiting11 (55%)
Completed6 (30%)
Recruiting2 (10%)
Active, not recruiting1 (5%)
not_applicable12 (60%)
Phase 33 (15%)
Not Specified3 (15%)
Phase 11 (5%)
Phase 21 (5%)